9. Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine:dream or reality? Ann Oncol, 2014, 25:2304-2313.
[2]
10. Khoja L, Lorigan P, Dive C, et al. Circulating tumour cells as tumour biomarkers in melanoma:detection methods and clinical relevance. Ann Oncol, 2015, 26:33-39.
[3]
15. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res, 2011, 13:228.
[4]
16. Han Y, Su C, Liu Z. Methods for detection of circulating cells in non-small cell lung cancer. Front Biosci (Landmark Ed), 2014, 19:896-903.
[5]
18. Kuniyoshi RK, Gehrke FDe S, Alves BC, et al. Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer. Tumour Biol, 2015, 36:8075-8083.
[6]
19. Wang HY, Ahn S, Kim S, et al. Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay. Int J Clin Oncol, 2015, 20:878-890.
[7]
20. Marin-Aguilera M, Reig O, Lozano JJ, et al. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer. Oncotarget, 2015, 6:10604-10616.
[8]
23. Sequist LV, Nagrath S, Toner M, et al. The CTC-chip:an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol, 2009, 4:281-283.
[9]
24. Mascalchi M, Falchini M, Maddau C, et al. Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC. J Cancer Res Clin Oncol, 2016, 142:195-200.
[10]
25. Muinelo-Romay L, Vieito M, Abalo A, et al. Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment. Cancers (Basel), 2014, 6:153-165.
[11]
26. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol, 2011, 29:1556-1563.
[12]
32. Engel J, Richters A, Getlik M, et al. Targeting drug resistance in EGFR with covalent inhibitors:a structure-based design approach. J Med Chem, 2015, 58:6844-6863.
[13]
33. Ishii H, Azuma K, Sakai K, et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC:Correlation with paired tumor samples. Oncotarget, 2015, 6:30850-30858.
[14]
34. Freidin MB, Freydina DV, Leung M, et al. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem, 2015, 61:1299-1304.
[15]
1. Ilie M, Hofman V, Long E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med, 2014, 2:107.
[16]
2. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection:clinical impact and future directions. Cancer Lett, 2007, 253:180-204.
[17]
3. Toss A, Mu Z, Fernandez S, et al. CTC enumeration and characterization:moving toward personalized medicine. Ann Transl Med, 2014, 2:108.
[18]
4. Fusi A, Metcalf R, Krebs M, et al. Clinical utility of circulating tumour cell detection in non-small-cell lung cancer. Curr Treat Options Oncol, 2013, 14:610-622.
[19]
5. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res, 2011, 17:827-835.
[20]
6. Yoon SO, Kim YT, Jung KC, et al. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer, 2011, 71:209-216.
[21]
7. Adamczyk LA, Williams H, Frankow A, et al. Current understanding of circulating tumor cells-potential value in malignancies of the central nervous system. Front Neurol, 2015, 6:174.
[22]
8. Sleijfer S, Gratama JW, Sieuwerts AM, et al. Circulating tumour cell detection on its way to routine diagnostic implementation? Eur J Cancer, 2007, 43:2645-2650.
[23]
46. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem, 2015, 61:112-123.
[24]
47. Huang WL, Wei F, Wong DT, et al. The emergent landscape of detecting EGFR mutations using circulating tumor DNA in lung cancer. Biomed Res Int, 2015, 2015:340732.
[25]
48. Madic J, Kiialainen A, Bidard FC, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer, 2015, 136:2158-2165.
[26]
11. Mazzini C, Pinzani P, Salvianti F, et al. Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method. Cancers (Basel), 2014, 6:323-332.
[27]
12. Gertler R, Rosenberg R, Fuehrer K, et al. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res, 2003, 162:149-155.
[28]
13. Zheng S, Lin HK, Lu B, et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices, 2011, 13:203-213.
[29]
14. Ma YC, Wang L, Yu FL. Recent advances and prospects in the isolation by size of epithelial tumor cells (ISET) methodology. Technol Cancer Res Treat, 2013, 12:295-309.
[30]
17. Harouaka R, Kang Z, Zheng SY, et al. Circulating tumor cells:advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther, 2014, 141:209-221.
[31]
21. Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res, 2007, 13:2023-2029.
[32]
22. Lu Y, Liang H, Yu T, et al. Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry. Cancer, 2015, 121:3036-3045.
[33]
27. Chen X, Wang X, He H, et al. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer. PLoS One, 2015, 10:e0126276.
[34]
28. Chen X, Zhou F, Li X, et al. Folate receptor-positive circulating tumor cell detected by LT-PCR-based method as a diagnostic biomarker for non-small-cell lung cancer. J Thorac Oncol, 2015, 10:1163-1171.
[35]
29. Yu Y, Chen Z, Dong J, et al. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol, 2013, 6:697-702.
[36]
30. Cheng M, Liu L, Yang HS, et al. Circulating tumor cells are associated with bone metastasis of lung cancer. Asian Pac J Cancer Prev, 2014, 15:6369-6374.
[37]
31. Botting GM, Rastogi I, Chhabra G, et al. Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer. PLoS One, 2015, 10:e0136155.
[38]
35. Pailler E, Adam J, Barthelemy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol, 2013, 31:2273-2281.
[39]
36. Marchetti A, Del Grammastro M, Felicioni L, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing:toward a real-time liquid biopsy for treatment. PLoS One, 2014, 9:e103883.
[40]
37. Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer:association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res, 2012, 18:2391-2401.
[41]
38. Warth A, Cortis J, Soltermann A, et al. Tumour cell proliferation (Ki-67) in non-small cell lung cancer:a critical reappraisal of its prognostic role. Br J Cancer, 2014, 111:1222-1229.
[42]
39. Li L, Liu D, Qiu ZX, et al. The prognostic role of mTOR and p-mTOR for survival in non-small cell lung cancer:a systematic review and meta-analysis. PLoS One, 2015, 10:e0116771.
[43]
40. Qiu ZX, Zhang K, Qiu XS, et al. The prognostic value of phosphorylated AKT expression in non-small cell lung cancer:a meta-analysis. PLoS One, 2013, 8:e81451.
[44]
41. Lee HW, Lee EH, Lee JH, et al. Prognostic significance of phosphorylated 4E-binding protein 1 in non-small cell lung cancer. Int J Clin Exp Pathol, 2015, 8:3955-3962.
[45]
42. Juan O, Vidal J, Gisbert R, et al. Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine. Clin Transl Oncol, 2014, 16:637-643.
[46]
43. Li J, Shi SB, Shi WL, et al. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer. Transl Res, 2014, 163:27-35.
[47]
44. Zhu WF, Li J, Yu LC, et al. Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients. Tumour Biol, 2014, 35:1211-1219.
[48]
45. Dorner AJ, Badola S, Niu H. Characterization of circulating tumor DNA for genetic assessment of solid tumors. Clin Pharmacol Ther, 2015, 98:16-18.
